RYTM Rhythm Pharmaceuticals, Inc.

Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Stanley Druckenmiller’s Duquesne Family Office recently filed its 13F for the second quarter. The firm opened new stakes in more than 40 stocks. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) and Definium Therapeutics, Inc. (NASDAQ:DFTX) are the notable ones in the healthcare space. Duquesne bought 203,618 shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) worth $22.6 million. The fund also […]

Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed medicine Imcivree.

Moderna upgraded, Allstate downgraded: Wall Street's top analyst calls

NVIDIA's blockbuster earnings sent shockwaves through tech on Thursday, but Wall Street analysts were busy reshaping the landscape elsewhere, issuing a flurry of upgrades, downgrades, and fresh initiations across energy, crypto infrastructure, banking, and biotech.

Rhythm Pharmaceuticals has delivered very strong long-term share price gains, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. The stock is up about 7x over 5 years, which puts extra focus on whether recent gains already reflect much of the company story. Approval of IMCIVREE for acquired hypothalamic obesity in Japan may support expectations for future revenue growth, while execution risk around pricing, uptake...

Could this little-known biotech be a hidden gem?

Rhythm Pharmaceuticals (NASDAQ:RYTM) is expanding commercialization of its rare-disease obesity treatment IMCIVREE while advancing additional melanocortin-4 receptor, or MC4R, agonists through development, Chief Financial Officer Hunter Smith said during a Canaccord Genuity fireside chat. Smith sai

IMCIVREE revenue surged 19% sequentially as HO patient adoption accelerated post-approval.

Moby summary of Rhythm Pharmaceuticals, Inc.'s Q2 2026 earnings call

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, up 19% sequentially from $60.1 million in the first quarter, as the company cited an early positive reception to its U.S. launch in acquired hypothalamic obesity, or HO. Chief E

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +9.88% and +6.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

In early August 2026, Rhythm Pharmaceuticals is scheduled to report quarterly results that analysts expect will show higher revenue but a year-over-year earnings decline, with many anticipating a potential earnings beat versus consensus estimates. This combination of rising sales and the prospect of outperforming forecasts, despite weaker earnings, has drawn fresh attention to how Rhythm’s growth profile and cost base are evolving. We’ll now examine how anticipation of an earnings beat,...

Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street analysts are reshuffling their bets ahead of the busiest earnings week of the quarter, and the moves span everything from legacy automakers to crypto miners to space launch companies. Find out which names just got upgraded, downgraded, or picked up for the first time.